244 related articles for article (PubMed ID: 15364685)
1. Long-term treatment of restless legs syndrome with dopamine agonists.
Ondo W; Romanyshyn J; Vuong KD; Lai D
Arch Neurol; 2004 Sep; 61(9):1393-7. PubMed ID: 15364685
[TBL] [Abstract][Full Text] [Related]
2. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome.
Bliwise DL; Freeman A; Ingram CD; Rye DB; Chakravorty S; Watts RL
Sleep Med; 2005 Mar; 6(2):141-7. PubMed ID: 15716217
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
[TBL] [Abstract][Full Text] [Related]
5. Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study).
Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2008 Jul; 9(5):537-41. PubMed ID: 18276187
[TBL] [Abstract][Full Text] [Related]
6. Long-term open-label study of pramipexole in patients with primary restless legs syndrome.
Inoue Y; Kuroda K; Hirata K; Uchimura N; Kagimura T; Shimizu T
J Neurol Sci; 2010 Jul; 294(1-2):62-6. PubMed ID: 20451927
[TBL] [Abstract][Full Text] [Related]
7. [Effect of high dose pergolide mesilate on restless legs syndrome associated with Parkinson disease].
Imamura A; Tsuboi Y; Tanaka M; Obata T; Yamada T
Rinsho Shinkeigaku; 2007 Apr; 47(4):156-9. PubMed ID: 17511286
[TBL] [Abstract][Full Text] [Related]
8. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.
Montplaisir J; Karrasch J; Haan J; Volc D
Mov Disord; 2006 Oct; 21(10):1627-35. PubMed ID: 16874755
[TBL] [Abstract][Full Text] [Related]
9. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome.
Garcia-Borreguero D; Grunstein R; Sridhar G; Dreykluft T; Montagna P; Dom R; Lainey E; Moorat A; Roberts J
Sleep Med; 2007 Nov; 8(7-8):742-52. PubMed ID: 17512789
[TBL] [Abstract][Full Text] [Related]
10. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome.
Silver N; Allen RP; Senerth J; Earley CJ
Sleep Med; 2011 May; 12(5):440-4. PubMed ID: 21239226
[TBL] [Abstract][Full Text] [Related]
11. Effect of non-ergot dopamine agonists on health-related quality of life of patients with restless legs syndrome.
Talati R; Phung OJ; Mather J; Coleman CI
Ann Pharmacother; 2009 May; 43(5):813-21. PubMed ID: 19401472
[TBL] [Abstract][Full Text] [Related]
12. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.
Trenkwalder C; Stiasny-Kolster K; Kupsch A; Oertel WH; Koester J; Reess J
Mov Disord; 2006 Sep; 21(9):1404-10. PubMed ID: 16755554
[TBL] [Abstract][Full Text] [Related]
13. The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels.
Frauscher B; Gschliesser V; Brandauer E; El-Demerdash E; Kaneider M; Rücker L; Poewe W; Högl B
Sleep Med; 2009 Jun; 10(6):611-5. PubMed ID: 19200780
[TBL] [Abstract][Full Text] [Related]
14. [Restless legs: recent advances in basic research and therapy].
Sieb JP
Med Monatsschr Pharm; 2010 Apr; 33(4):133-9. PubMed ID: 20429403
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points--data from the ropinirole clinical trial programme.
Giorgi L; Ritchie SY; Kirsch JM
Curr Med Res Opin; 2006 Oct; 22(10):1867-77. PubMed ID: 17022844
[TBL] [Abstract][Full Text] [Related]
16. Appropriate use of dopamine agonists and levodopa in restless legs syndrome in an ambulatory care setting.
Molokwu OC
Ann Pharmacother; 2008 May; 42(5):627-32. PubMed ID: 18381842
[TBL] [Abstract][Full Text] [Related]
17. Methadone for refractory restless legs syndrome.
Ondo WG
Mov Disord; 2005 Mar; 20(3):345-8. PubMed ID: 15580610
[TBL] [Abstract][Full Text] [Related]
18. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.
Manconi M; Ferri R; Zucconi M; Oldani A; Fantini ML; Castronovo V; Ferini-Strambi L
Sleep Med; 2007 Aug; 8(5):491-7. PubMed ID: 17512780
[TBL] [Abstract][Full Text] [Related]
19. Restless legs syndrome: clinical experience with long-term treatment.
Clavadetscher SC; Gugger M; Bassetti CL
Sleep Med; 2004 Sep; 5(5):495-500. PubMed ID: 15341896
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of Restless legs syndrome in patients with Parkinson's disease.
Nomura T; Inoue Y; Nakashima K
J Neurol Sci; 2006 Dec; 250(1-2):39-44. PubMed ID: 16899256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]